Utah Code § 26B-4-243: Guidance for treatment with medical cannabis.

The department, in consultation with the Center for Medical Cannabis Research created in Section 53H-4-206, shall:

(1) develop evidence-based guidance for treatment with medical cannabis based on the latest medical research that shall include:

(a) for each qualifying condition, a summary of the latest medical research regarding the treatment of the qualifying condition with medical cannabis;

(b) risks, contraindications, side effects, and adverse reactions that are associated with medical cannabis use; and

(c) potential drug interactions between medical cannabis and medications that have been approved by the United States Food and Drug Administration;

(2) educate recommending medical providers, pharmacy medical providers, medical cannabis cardholders, and the public regarding:

(a) the evidence-based guidance for treatment with medical cannabis described in Subsection (1)(a);

(b) relevant warnings and safety information related to medical cannabis use; and

(c) other topics related to medical cannabis use as determined by the department; and

(3) develop patient product information inserts for medical cannabis products:

(a) in consultation with the cannabis processing facility that created the product; and

(b) that do not contain proprietary information about the product.